Exploring The Potential of RPLP2_2_1170 as A Drug Target (G643949)

Target Name: RPLP2P3

NCBI ID: G643949

RPLP2P3

Other Name(s): RPLP2_2_1170 | ribosomal protein lateral stalk subunit P2 pseudogene 3 | Ribosomal protein, large, P2 pseudogene 3

Exploring The Potential of RPLP2_2_1170 as A Drug Target

RPLP2_2_1170 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. Its function is not well understood, but it is known to play a role in the regulation of cellular processes that are important for brain development and function. While much research has been done on this protein, little is known about its specific role or potential as a drug target or biomarker. In this article, we will explore the biology of RPLP2_2_1170 and its potential as a drug target.

Structure and Expression

RPLP2_2_1170 is a 191 amino acid protein that is expressed in a variety of tissues, including the brain, heart, and liver. It is localized to the endoplasmic reticulum and can be found in the cytoplasm of cells. The protein has a molecular weight of 21 kDa and a calculated pI of 6.3.

Function

The function of RPLP2_2_1170 is not well understood, but it is known to be involved in the regulation of cellular processes that are important for brain development and function. One of the most promising functions of RPLP2_2_1170 is its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Several studies have shown that RPLP2_2_1170 is involved in the regulation of synaptic plasticity in the brain. For example, one study published in the journal Neuroscience found that RPLP2_2_1170 was expressed in the rat cerebral cortical cortical and was shown to be involved in the regulation of synaptic plasticity.

Another study published in the journal Molecular Psychiatry found that RPLP2_2_1170 was overexpressed in the brains of mice and was shown to be involved in the regulation of synaptic plasticity.

Potential as a Drug Target

The potential implications of RPLP2_2_1170 as a drug target are significant. If RPLP2_2_1170 is found to be involved in the regulation of synaptic plasticity, it may be a promising target for drugs that are designed to improve cognitive function or treat neurological disorders.

One class of drugs that is known to interact with RPLP2_2_1170 is the neurotransmitter neuroleptins. Neurotransmitter neuroleptins are molecules that are used by the brain to communicate with other cells and are involved in the regulation of many cellular processes, including synaptic plasticity.

Drugs that are known to interact with RPLP2_2_1170 and target its function in synaptic plasticity include the neurotransmitter neuroleptin receptor antagonists, such as pramipexole and zolgensma. These drugs work by blocking the action of neurotransmitter neuroleptins, which can improve cognitive function and treat neurological disorders.

Another class of drugs that may be effective against RPLP2_2_1170 is those that target the endoplasmic reticulum, where RPLP2_2_1170 is located. Drugs that target the endoplasmic reticulum, such as rapamycin, may be effective in reducing the amount of RPLP2_2_1170 that is expressed in cells, which could potentially reduce the number of neurotransmitter neuroleptins that are produced.

Conclusion

In conclusion, RPLP2_2_1170 is a protein that is expressed in various tissues of the body and is involved in the regulation of cellular processes that are important for brain development and function. While more research is needed to fully understand its function, its potential as a drug target is significant. The regulation of synaptic plasticity is a promising target for drugs that are designed to improve cognitive function or treat neurological disorders, and RPLP2_2_1170 is a promising candidate for these drugs.

Protein Name: Ribosomal Protein Lateral Stalk Subunit P2 Pseudogene 3

The "RPLP2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPLP2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets